002773 康弘药业
未开盘 02-05 09:30:00
资讯
新帖
简况
康弘药业:截至2026年1月30日,公司股东户数约为3.45万户
证券之星 · 02-03 16:57
康弘药业:截至2026年1月30日,公司股东户数约为3.45万户
股市必读:康弘药业(002773)1月23日董秘有最新回复
证券之星 · 01-26
股市必读:康弘药业(002773)1月23日董秘有最新回复
康弘药业:KH110项目Ⅲ期临床试验正在全国多家医院开展
证券之星 · 01-23
康弘药业:KH110项目Ⅲ期临床试验正在全国多家医院开展
信达证券:首次覆盖康弘药业给予买入评级
证券之星 · 01-20
信达证券:首次覆盖康弘药业给予买入评级
康弘药业(002773.SZ):度普利尤单抗KH816注射液药物临床试验获批
智通财经网 · 01-14
康弘药业(002773.SZ):度普利尤单抗KH816注射液药物临床试验获批
康弘药业:截至2026年1月9日股东户数为33,118户
证券之星 · 01-12
康弘药业:截至2026年1月9日股东户数为33,118户
康弘药业(002773)披露完成工商变更登记及公司章程修订,1月9日股价上涨2.88%
证券之星 · 01-09
康弘药业(002773)披露完成工商变更登记及公司章程修订,1月9日股价上涨2.88%
股市必读:康弘药业(002773)1月7日董秘有最新回复
证券之星 · 01-08
股市必读:康弘药业(002773)1月7日董秘有最新回复
康弘药业:截至目前公司没有脑机接口相关业务
证券之星 · 01-07
康弘药业:截至目前公司没有脑机接口相关业务
康弘药业(002773.SZ):基因治疗创新产品KH631眼用注射液获药物临床试验批准
智通财经网 · 01-05
康弘药业(002773.SZ):基因治疗创新产品KH631眼用注射液获药物临床试验批准
异动快报:康弘药业(002773)1月5日11点23分触及涨停板
证券之星 · 01-05
异动快报:康弘药业(002773)1月5日11点23分触及涨停板
股市必读:康弘药业(002773)12月31日董秘有最新回复
证券之星 · 01-05
股市必读:康弘药业(002773)12月31日董秘有最新回复
每周股票复盘:康弘药业(002773)康弘生物获准开展高剂量临床试验
证券之星 · 01-03
每周股票复盘:康弘药业(002773)康弘生物获准开展高剂量临床试验
康弘药业:截至2025年12月19日股东户数为28,477户
证券之星 · 2025-12-31
康弘药业:截至2025年12月19日股东户数为28,477户
康弘药业(002773.SZ):康柏西普眼用注射液收到临床试验补充申请批准通知书
智通财经 · 2025-12-29
康弘药业(002773.SZ):康柏西普眼用注射液收到临床试验补充申请批准通知书
康弘药业最新公告:收到布瑞哌唑片的药品注册证书
证券之星 · 2025-12-25
康弘药业最新公告:收到布瑞哌唑片的药品注册证书
康弘药业(002773)披露关于注销部分募集资金专用账户的公告,12月24日股价下跌0.29%
证券之星 · 2025-12-24
康弘药业(002773)披露关于注销部分募集资金专用账户的公告,12月24日股价下跌0.29%
康弘药业(002773)披露变更注册资本及修订公司章程公告,12月19日股价上涨3.44%
证券之星 · 2025-12-19
康弘药业(002773)披露变更注册资本及修订公司章程公告,12月19日股价上涨3.44%
康弘药业:KH110正在按计划进行临床研究
证券之星 · 2025-12-18
康弘药业:KH110正在按计划进行临床研究
康弘药业最新公告:子公司弘基生物收到药物临床试验批准通知书
证券之星 · 2025-12-12
康弘药业最新公告:子公司弘基生物收到药物临床试验批准通知书
加载更多
公司概况
公司名称:
成都康弘药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2015-06-26
主营业务:
成都康弘药业集团股份有限公司的主营业务是药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司的主要产品是康柏西普眼用注射液、利非司特滴眼液、普拉洛芬滴眼液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、氢溴酸伏硫西汀片、草酸艾司西酞普兰片、草酸艾司西酞普兰口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、盐酸普拉克索缓释片、右佐匹克隆片等药品和医疗器械。
发行价格:
13.62
{"stockData":{"symbol":"002773","market":"SZ","secType":"STK","nameCN":"康弘药业","latestPrice":28.74,"timestamp":1770253212000,"preClose":28.74,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":687000000,"shares":921000000,"eps":1.3573,"marketStatus":"未开盘","change":0,"latestTime":"02-05 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":1.3573,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770255000000},"marketStatusCode":0,"adr":0,"adjPreClose":28.74,"symbolType":"stock","openAndCloseTimeList":[[1770255000000,1770262200000],[1770267600000,1770274800000]],"highLimit":31.61,"lowLimit":25.87,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":921320954,"isCdr":false,"pbRate":2.89,"roa":"--","peRate":21.17439,"roe":"11.55%","epsLYR":1.3,"committee":0,"marketValue":26479000000,"turnoverRate":0,"status":2,"floatMarketCap":19740000000},"requestUrl":"/m/hq/s/002773","defaultTab":"news","newsList":[{"id":"2608267508","title":"康弘药业:截至2026年1月30日,公司股东户数约为3.45万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2608267508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608267508?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:57","pubTimestamp":1770109033,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)02月03日在投资者关系平台上答复投资者关心的问题。投资者提问:请问最近的股东人数是多少?康弘药业回复:尊敬的投资者,您好!截至2026年1月30日,公司股东户数约为3.45万户。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300028575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","LU2148510915.USD","BK0196","BK0239","LU1064131003.USD","002773","LU1064130708.USD"],"gpt_icon":0},{"id":"2606265151","title":"股市必读:康弘药业(002773)1月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606265151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606265151?lang=zh_cn&edition=full","pubTime":"2026-01-26 03:22","pubTimestamp":1769368930,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,康弘药业报收于32.58元,上涨1.65%,换手率1.36%,成交量9.34万手,成交额3.03亿元。目前该项目Ⅲ期临床试验正在全国多家医院开展,招募对象为50-80岁的轻、中度阿尔茨海默病患者。相关试验信息已按国家要求登记并公开于国家药品监督管理局“药物临床试验登记与信息公开平台”。当日关注点来自交易信息汇总:1月23日主力资金净流入209.18万元,显示主力小幅加仓。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","002773","BK0239","BK0197","LU1064130708.USD","BK0196","LU1064131003.USD"],"gpt_icon":0},{"id":"2605428108","title":"康弘药业:KH110项目Ⅲ期临床试验正在全国多家医院开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2605428108","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605428108?lang=zh_cn&edition=full","pubTime":"2026-01-23 11:45","pubTimestamp":1769139906,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业01月23日在投资者关系平台上答复投资者关心的问题。感谢您对公司KH110项目的关注。目前该项目Ⅲ期临床试验正在全国多家医院开展,招募对象为50-80岁的轻、中度阿尔茨海默病患者。相关试验信息已按国家要求登记并公开于国家药品监督管理局“药物临床试验登记与信息公开平台”。如您或相关人员有意向参与,建议通过该平台进一步了解具体入组标准,并前往就近的研究医院进行评估。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300016289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","LU2148510915.USD","BK0196","BK0239","LU1064131003.USD","002773","LU1064130708.USD"],"gpt_icon":0},{"id":"2604159574","title":"信达证券:首次覆盖康弘药业给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2604159574","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604159574?lang=zh_cn&edition=full","pubTime":"2026-01-20 07:36","pubTimestamp":1768865760,"startTime":"0","endTime":"0","summary":"信达证券股份有限公司唐爱金近期对康弘药业进行研究并发布了研究报告《公司首次覆盖报告:深耕眼科黄金赛道,基因治疗创新管线打开新空间》,首次覆盖康弘药业给予买入评级。康弘药业(00277 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260120/c674141365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["002773","601059"],"gpt_icon":0},{"id":"2603692701","title":"康弘药业(002773.SZ):度普利尤单抗KH816注射液药物临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2603692701","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603692701?lang=zh_cn&edition=full","pubTime":"2026-01-14 18:47","pubTimestamp":1768387646,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业 发布公告,近日,公司全资子公司成都康弘生物科技有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》,该药品名称:KH816注射液。KH816注射液是康弘生物研发的度普利尤单抗生物类似药。度普利尤单抗通过I型受体抑制IL-4信号传导,并通过II型受体抑制IL-4和IL-13信号传导。利用度普利尤单抗阻断IL-4Rα,可抑制IL-4和IL-13细胞因子诱导的炎性反应,包括促炎细胞因子、趋化因子、一氧化氮和IgE释放。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康弘药业(002773.SZ):度普利尤单抗KH816注射液药物临床试验获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","002773","BK0197","BK0196"],"gpt_icon":0},{"id":"2602356930","title":"康弘药业:截至2026年1月9日股东户数为33,118户","url":"https://stock-news.laohu8.com/highlight/detail?id=2602356930","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602356930?lang=zh_cn&edition=full","pubTime":"2026-01-12 09:00","pubTimestamp":1768179650,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问:股东人数怎么还不更新啊?截止20260年1月8号,股东人数是多少呢?康弘药业回复:尊敬的投资者,您好!截至2026年1月9日,公司股东户数为33,118户。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200002004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","002773","BK0239","LU2148510915.USD","LU1064130708.USD","BK0197","BK0196"],"gpt_icon":0},{"id":"2602329252","title":"康弘药业(002773)披露完成工商变更登记及公司章程修订,1月9日股价上涨2.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602329252","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602329252?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:32","pubTimestamp":1767951175,"startTime":"0","endTime":"0","summary":"公司近日发布公告称,成都康弘药业集团股份有限公司于2025年12月3日召开第八届董事会第十四次会议,于2025年12月19日召开2025年第一次临时股东会,审议通过了《关于变更公司注册资本及修订〈公司章程〉的议案》。目前,公司已完成工商变更登记手续。本次修订主要涉及公司注册资本由919,869,004.00元变更为921,320,954.00元,股份总数相应变更,并对章程中关于股东权利、董事会、股东会、独立董事、审计委员会等内容进行了调整和完善。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900028541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","BK0197","BK0196","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","BK0239"],"gpt_icon":0},{"id":"2601834523","title":"股市必读:康弘药业(002773)1月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601834523","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601834523?lang=zh_cn&edition=full","pubTime":"2026-01-08 02:44","pubTimestamp":1767811452,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘,康弘药业报收于33.37元,下跌1.13%,换手率1.79%,成交量12.31万手,成交额4.15亿元。董秘最新回复投资者: 公司业务涉及到脑机接口吗?截至目前,公司没有题述相关的业务。感谢您的关注与支持!当日关注点来自交易信息汇总:1月7日主力资金净流出230.45万元,游资积极介入,净流入4569.83万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800001305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","002773","BK0196","BK0197","BK0239","LU2148510915.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2601844954","title":"康弘药业:截至目前公司没有脑机接口相关业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2601844954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601844954?lang=zh_cn&edition=full","pubTime":"2026-01-07 08:43","pubTimestamp":1767746588,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)01月07日在投资者关系平台上答复投资者关心的问题。投资者提问:公司业务涉及到脑机接口吗?康弘药业回复:尊敬的投资者,您好!截至目前,公司没有题述相关的业务。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700005000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","002773","LU1064131003.USD","BK0197","LU2148510915.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2601074791","title":"康弘药业(002773.SZ):基因治疗创新产品KH631眼用注射液获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2601074791","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601074791?lang=zh_cn&edition=full","pubTime":"2026-01-05 12:06","pubTimestamp":1767585976,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)发布公告,近日,公司子公司成都弘基生物科技有限公司(以下简称“弘基生物”)收到国家药品监督管理局签发的《药物临床试验批准通知书》,涉及药品:KH631眼用注射液。将开展适用于治疗糖尿病黄斑水肿(DME)的临床试验。","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/22.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/22.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康弘药业(002773.SZ):基因治疗创新产品KH631眼用注射液获药物临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","LU2148510915.USD","LU1064131003.USD","BK0196","002773","LU1064130708.USD","BK0197"],"gpt_icon":0},{"id":"2601107141","title":"异动快报:康弘药业(002773)1月5日11点23分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2601107141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601107141?lang=zh_cn&edition=full","pubTime":"2026-01-05 11:25","pubTimestamp":1767583516,"startTime":"0","endTime":"0","summary":"证券之星1月5日盘中消息,11点23分康弘药业触及涨停板。其所属行业生物制品目前上涨。该股为医疗器械,创新药,眼科概念热股,当日医疗器械概念上涨4.6%,创新药概念上涨3.74%,眼科概念上涨2.94%。12月31日的资金流向数据方面,主力资金净流入1193.22万元,占总成交额8.65%,游资资金净流入673.26万元,占总成交额4.88%,散户资金净流出1866.48万元,占总成交额13.54%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500010687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0239","BK0197","BK0196","002773","LU1064131003.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2601029707","title":"股市必读:康弘药业(002773)12月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601029707","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601029707?lang=zh_cn&edition=full","pubTime":"2026-01-05 02:59","pubTimestamp":1767553148,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,康弘药业报收于29.97元,上涨0.0%,换手率0.67%,成交量4.63万手,成交额1.38亿元。董秘最新回复投资者: 请问截至2025年12月10日、20日,股东户数分别是多少?截至2025年12月10日,公司股东户数为28,118户;截至2025年12月19日,公司股东户数为28,477户。公司2025年年度报告将于2026年4月23日披露,详细情况敬请关注公司披露的相关公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500000927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU1064130708.USD","002773","LU2148510915.USD","BK0197","BK0196","BK0239"],"gpt_icon":0},{"id":"2600067614","title":"每周股票复盘:康弘药业(002773)康弘生物获准开展高剂量临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067614","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600067614?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:44","pubTimestamp":1767379452,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,康弘药业报收于29.97元,较上周的30.76元下跌2.57%。本周关注点公司公告汇总:子公司获准开展高剂量康柏西普眼用注射液临床试验。公司公告汇总关于子公司收到药物临床试验补充申请批准通知书的公告成都康弘药业集团股份有限公司全资子公司成都康弘生物科技有限公司收到国家药品监督管理局签发的康柏西普眼用注射液《药物临床试验补充申请批准通知书》,同意开展高剂量康柏西普眼用注射液的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","002773","BK0197","BK0196"],"gpt_icon":0},{"id":"2595172207","title":"康弘药业:截至2025年12月19日股东户数为28,477户","url":"https://stock-news.laohu8.com/highlight/detail?id=2595172207","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595172207?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:57","pubTimestamp":1767171442,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)12月31日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截至2025年12月10日、20日,股东户数分别是多少?康弘药业回复:尊敬的投资者,您好!截至2025年12月10日,公司股东户数为28,118户;截至2025年12月19日,公司股东户数为28,477户。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100029749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","BK0197","BK0239","BK0196"],"gpt_icon":0},{"id":"2595206934","title":"康弘药业(002773.SZ):康柏西普眼用注射液收到临床试验补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2595206934","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595206934?lang=zh_cn&edition=full","pubTime":"2025-12-29 11:54","pubTimestamp":1766980474,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)发布公告,近日,公司全资子公司成都康弘生物科技有限公司(简称“康弘生物”)收到国家药品监督管理局签发的康柏西普眼用注射液《药物临床试验补充申请批准通知书》。康柏西普眼用注射液是公司全资子公司康弘生物自主研发的具有完全自主知识产权的1类生物创新药,该产品能有效地与血管及组织中的VEGF结合,阻断由VEGF介导的促进新生血管出芽和生长的信号传递。本次为高剂量康柏西普眼用注射液在临床应用上的探索,有望提升患者用药依从性、减轻医疗负担。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康弘药业(002773.SZ):康柏西普眼用注射液收到临床试验补充申请批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","002773","LU2148510915.USD","BK0239","BK0197","BK0196","LU1064131003.USD"],"gpt_icon":0},{"id":"2594239627","title":"康弘药业最新公告:收到布瑞哌唑片的药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2594239627","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594239627?lang=zh_cn&edition=full","pubTime":"2025-12-25 18:41","pubTimestamp":1766659274,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)公告称,公司于近日收到国家药品监督管理局签发的布瑞哌唑片的《药品注册证书》,批准注册。该药品用于治疗成人精神分裂症,注册分类为化学药品4类。此次获批丰富了公司的产品管线,但医药产品的生产销售情况可能受到市场环境变化等因素影响,存在不确定性,投资者需谨慎决策。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500028450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU1064130708.USD","LU2148510915.USD","002773","BK0196","BK0239","BK0197"],"gpt_icon":0},{"id":"2593702934","title":"康弘药业(002773)披露关于注销部分募集资金专用账户的公告,12月24日股价下跌0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593702934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593702934?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:25","pubTimestamp":1766586312,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘,康弘药业报收于30.74元,较前一交易日下跌0.29%,最新总市值为283.21亿元。该股当日开盘30.83元,最高31.27元,最低30.61元,成交额达1.56亿元,换手率为0.73%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400040814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0196","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","002773"],"gpt_icon":0},{"id":"2592198694","title":"康弘药业(002773)披露变更注册资本及修订公司章程公告,12月19日股价上涨3.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592198694","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592198694?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:28","pubTimestamp":1766154539,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘,康弘药业报收于30.98元,较前一交易日上涨3.44%,最新总市值为285.43亿元。该股当日开盘29.95元,最高31.27元,最低29.9元,成交额达2.7亿元,换手率为1.27%。近日,成都康弘药业集团股份有限公司召开2025年第一次临时股东会,审议通过《关于变更公司注册资本及修订<公司章程>的议案》和《关于修订公司部分内部制度的议案》。两项议案均获通过,其中公司章程修订及部分内部制度议案获得特别决议通过,其余子议案为普通决议事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","002773","BK0239","BK0197","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2592977403","title":"康弘药业:KH110正在按计划进行临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2592977403","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592977403?lang=zh_cn&edition=full","pubTime":"2025-12-18 19:00","pubTimestamp":1766055630,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)12月18日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好!贵公司治疗阿兹海默症的药物已进入临床3期,进展如何?药理咋样?谢谢!康弘药业回复:尊敬的投资者,您好!公司KH110(治疗阿尔茨海默症(Alzheimersdisease,AD))正在按计划进行临床研究,由于药品从研发、临床试验、审评和审批的结果以及时间都具有一定的不确定性,敬请广大投资者谨慎决策,注意投资风险。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800029495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0196","LU2148510915.USD","LU1064130708.USD","BK0239","BK0197","002773"],"gpt_icon":0},{"id":"2590505254","title":"康弘药业最新公告:子公司弘基生物收到药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505254","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590505254?lang=zh_cn&edition=full","pubTime":"2025-12-12 20:09","pubTimestamp":1765541397,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)公告称,公司子公司成都弘基生物科技有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》,同意开展糖尿病黄斑水肿(DME)、糖尿病视网膜病变(DR)的临床试验。KH658眼用注射液是弘基生物自主研发的基因治疗创新产品,属于治疗用生物制品1类。药品从研发、临床试验、审评和审批的结果以及时间具有不确定性,敬请广大投资者谨慎决策,注意投资风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200036078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0239","LU2148510915.USD","LU1064130708.USD","002773","BK0197","BK0196"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770253258291,"stockEarnings":[{"period":"1week","weight":-0.0527},{"period":"1month","weight":-0.1283},{"period":"3month","weight":-0.0865},{"period":"6month","weight":-0.3202},{"period":"1year","weight":0.5206},{"period":"ytd","weight":-0.041}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":0.0196},{"period":"3month","weight":0.0236},{"period":"6month","weight":0.1285},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0336}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都康弘药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34500人(较上一季度增加4.17%)","perCapita":"19908股","listingDate":"2015-06-26","address":"四川省成都市金牛区蜀西路108号","registeredCapital":"92132万元","survey":" 成都康弘药业集团股份有限公司的主营业务是药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司的主要产品是康柏西普眼用注射液、利非司特滴眼液、普拉洛芬滴眼液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、氢溴酸伏硫西汀片、草酸艾司西酞普兰片、草酸艾司西酞普兰口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、盐酸普拉克索缓释片、右佐匹克隆片等药品和医疗器械。","listedPrice":13.62},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康弘药业,002773,康弘药业股票,康弘药业股票老虎,康弘药业股票老虎国际,康弘药业行情,康弘药业股票行情,康弘药业股价,康弘药业股市,康弘药业股票价格,康弘药业股票交易,康弘药业股票购买,康弘药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}